UK biotech Juvenescence secures over $150m to develop therapies
Endpoints News - 21-May-2025Juvenescence expands pipeline and UAE presence with new funding to tackle age-related diseases
Juvenescence
Developing therapies against different aging related diseases
Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines.
Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life.
By focusing on early disease intervention and prevention, we are committed to transforming how we age, ensuring that added years are healthy and fulfilling.
Juvenescence Executive Team
- Greg Bailey, Co-founder, Executive Chairman
- Jim Mellon, Co-founder, Deputy Chairman
- Declan Doogan, Co-founder, Board Member
- Richard Marshall, Chief Executive Officer
- Gillian Dines, Chief Science Officer
- Steve Felstead, Chief Medical Officer
- Jeff Madwed, Senior Project Lead
- Rosalba Perrone, Senior Research Scientist
- Kersten Small, Project Leader
- David Gill, Chief Financial Officer
- Alexander Pickett, Managing Director
Visit website: https://www.juvlabs.com/
Details last updated 04-May-2019
Juvenescence News
AI alliance to redefine the future of ageing and therapeutics
Juvenescence - 16-Apr-2025M42 and Juvenescence join forces to accelerate precision medicine and longevity
Reason reports back from Age-Related Disease Therapeutics Summit 2023
Fight Aging! - 16-Jun-2023Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years
Summary of Jim Mellon presentation at Longevity Med Summit
Live Forever Club - 19-May-2023Urges individuals with resources and a desire to contribute positively to humanity to invest in the longevity industry
AgeX credit running out with substantial doubt it can continue
FierceBiotech - 15-Aug-2022Let's hope their research is either successful for the company or its successors
JuvLife Division raises 3.7 million euros for making antiaging product with Chrysea
Longevity Technology - 13-Jun-2022Metabolites induce autophagy, stimulate cellular regeneration for healthy ageing
Selah Therapeutics launched to focus on ketone-based therapies for heart disease
Longevity Technology - 13-May-2022Treatment options for diseases of aging - from the makers of metabolic switch
Breaking new ground in fibrotic disease treatments
Longevity Technology - 21-Mar-2022Juvenescence and MDI unite to tackle ageing-related fibrosis
FDA approved LyGenesis' phase 2a trials on liver failure patients
Longevity Technology - 30-Dec-2020Raised $11M funding which goes into trials and developing functional organs
Jim Mellon plans to take his longevity company Juvenescence public
CNBC - 29-Sep-2020The company with $170 million private funding has invested in various life extension therapies
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020General feeling that failures are bound to happen - but that their approaches can succeed
Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd
Juvenescence - 11-Jun-2020Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration
Orion College ageing research receives 1 million UK pounds from Jim Mellon
Lifespan.io (LEAF) - 18-May-2020He believes in the importance of boosting immunoresilience among elderly
Master Investor Magazine focuses on longevity in its Autumn edition
Master Investor - 01-Nov-2019Interesting articles and some useful investment opportunities
A mission to change the lives of 1 billion people
Telegraph - 23-Sep-2019Life extension technology will be expensive, so it'll create inequalities between poor, rich people
Today's 50 year-olds may live another 100 years
Forbes - 26-Aug-2019Good summary of some major investments in life extension companies
Juvenescence backs BYOMass with strategic investment
Juvenescence - 27-Mar-2019Advancing treatments for age-related diseases and healthy ageing
Aging focused biotechs forms AI based joint venture
FierceBiotech - 14-Aug-2018Groundbreaking research biotechs performs aging research together for longevity
FoxBio is developing small molecule drugs to target ageing diseases
Business Wire - 12-Jul-2018Antoxerene partners with Juvenescence to discover drugs that clear senescent cells
UK biotech company focused on developing anti-ageing therapies
PMLiVE - 12-Jun-2018LyGenesis seeks to use a patient’s own lymph nodes as bioreactors to grow functioning ectopic organs
Interview with Juvenescence author Jim Mellon
Medium - 17-May-2018Juvenescence Ltd is making investments in the future of rejuvenation and life extension technology
Silicon Valley and rich people invest to slow down ageing and live longer
This Is Money - 17-Mar-2018All the money in the world to fight ageing and death
British billionaire gambles on an anti-aging upstart
Endpoints News - 26-Jul-2017We are at an inflection point for the treatment of aging. We can generate molecules with specifi...
Mentioned in this Resource
Jim Mellon
British entrepreneur, author and philanthropist with interests across a number of industries
Juvenescence is also referenced in the following:
Selah Therapeutics
Company focused on novel ketone-based therapies for the treatment of heart diseases
Juvenescence Creations
Investing in the Future of Longevity – the Ketone Chapter
10-May-2022
Juvenescence webinar about the latest research and developments on future of longevity investment
Other people at Juvenescence
Topics mentioned on this page:
Ageing Research
